Requires notification by a prescriber or pharmacist of the substitution of one generic drug product for another generic drug product; requires both oral and written notification.
Summary
S05352 would amend the New York Education Law to require notice when a prescriber or pharmacist substitutes one generic drug product for another generic drug product that a patient has previously received. The notice must tell the patient that a different generic version has been prescribed or dispensed, and it must be provided both orally and in writing.
The bill is aimed at increasing transparency for patients about changes in their medications even when the drugs are therapeutically equivalent generics. It does not prohibit substitution; rather, it adds a communication requirement for prescribers and pharmacists and would take effect 90 days after becoming law.
Impact
The bill would add a new patient-notification requirement to section 6810 of the Education Law, affecting prescribers and pharmacists who dispense or authorize generic medications. It would create a new legal duty to disclose generic-to-generic substitutions in both oral and written form, likely affecting pharmacy practice, prescription counseling, and recordkeeping, while leaving existing substitution authority intact.
Sentiment
Based on the bill text and the absence of recorded debate or votes, the measure appears to be a straightforward consumer-notification proposal with an informational rather than regulatory or punitive focus. The caption and language suggest a patient-protection framing, and there is no evidence in the provided materials of organized opposition or support from committee discussion or floor action.
Contention
The main potential point of contention is the added administrative burden on prescribers and pharmacists, who would need to provide dual-format notice whenever a generic product is switched to another generic version. Another possible issue is whether the requirement is necessary given that generic drugs are generally considered interchangeable; supporters would likely emphasize patient awareness and continuity of care, while critics may question whether the mandate adds complexity without clear clinical benefit.
Requires that pharmacists get express written consent before substituting a drug product for a less expensive drug product, including biological products.
Amends the types of products which pharmacists may prescribe as substitute drugs or products to include "devices and supplies" and "therapeutically equivalent drugs and pharmaceuticals".
Amends the types of products which pharmacists may prescribe as substitute drugs or products to include "devices and supplies" and "therapeutically equivalent drugs and pharmaceuticals."
Requires insurers to cover the substitution of a brand name prescription drug when the federal food and drug administration has declared that there is a supply issue with a generic drug.
Prohibits a pharmacist from substituting any anti-epileptic drug for the prescribed anti-epileptic drug without notification of and the informed consent of the prescriber and patient or such patient's parent, guardian or spouse.